1. Immunotherapy for cSCC

2. This program will include a discussion of off-label treatment and investigational agents not approved by the FDA for use in the United States, and data that were presented in abstract form. These data should be considered preliminary until published in a peer-reviewed journal.

3. Introduction

4. Treatment Options for Locally Advanced cSCC

5. Clinical Features and Diagnosis

6. Precancerous Actinic Keratoses

7. Squamous Cell Carcinomas

8. Advanced cSCC

9. Role of Practitioners in Disease Identification

10. Risk Factors

11. Risk Factors to Watch

12. Considerations for Therapy

13. Current Treatment Options

14. Which Patients Are Candidates for Immunotherapy?

15. How Do Risks Factors Affect Pathophysiology?

16. Overview of Immune Checkpoint Response

17. Immune Checkpoint Pathway

18. Immune Checkpoint Blockade

19. Rationale for Checkpoint Inhibitor Studies

20. Phase 1: Cemiplimab (REGN2810) Study Design

21. Phase 1: Cemiplimab (REGN2810) Patient Population and Response

22. Phase 2 Cemiplimab

23. Ongoing Checkpoint Inhibitor Trials in cSCC

24. Concluding Remarks

25. Abbreviations

26. Abbreviations (cont)